RT @EuRefNetwork: Protocol for a placebe-controlled trial for #Tolvaptan use in children and adolescents with #ADPKD https://t.co/n2K9nw15JJ
RT @rheault_m: Clinical trial of tolvaptan in kids with ADPKD enrolling in Europe. Start saving your money now. Wholesale cost for drug is…
RT @rheault_m: Clinical trial of tolvaptan in kids with ADPKD enrolling in Europe. Start saving your money now. Wholesale cost for drug is…
Clinical trial of tolvaptan in kids with ADPKD enrolling in Europe. Start saving your money now. Wholesale cost for drug is $13000/month #KidneyWk https://t.co/H0ZWzI7LiJ https://t.co/6YlNgkRy4I
RT @EuRefNetwork: Protocol for a placebe-controlled trial for #Tolvaptan use in children and adolescents with #ADPKD https://t.co/n2K9nw15JJ
RT @EuRefNetwork: Protocol for a placebe-controlled trial for #Tolvaptan use in children and adolescents with #ADPKD https://t.co/n2K9nw15JJ
RT @EuRefNetwork: Protocol for a placebe-controlled trial for #Tolvaptan use in children and adolescents with #ADPKD https://t.co/n2K9nw15JJ
RT @EuRefNetwork: Protocol for a placebe-controlled trial for #Tolvaptan use in children and adolescents with #ADPKD https://t.co/n2K9nw15JJ
Protocol for a placebe-controlled trial for #Tolvaptan use in children and adolescents with #ADPKD https://t.co/n2K9nw15JJ
Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial https://t.co/G4MmBu1zY7
RT @ASPNeph: Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-par…
RT @ASPNeph: Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-par…
RT @ASPNeph: Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-par…
RT @ASPNeph: Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-par…
Widening the indication of tolvaptan Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial | SpringerLink htt
RT @ASPNeph: Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-par…
RT @ASPNeph: Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-par…
RT @ASPNeph: Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-par…
RT @ASPNeph: Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-par…
RT @ASPNeph: Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-par…
Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial https://t.co/LTF8Gmvfx3 #ADPKD
Tolvaptan use in children and adolescents with autosomal dominant… https://t.co/AKZoYrhXru #eprompt #paedmed
#EuropeanJournalOfPediatrics Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial https://t.co/9Yr8372gN2
Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial https://t.co/nyhJa83mKU
Eur J Pediatrics Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial https://t.co/77UegT9iY5